Open Door Salon
We have to apologize for the video quality. Ali's recording corrupted. GLP-1s hit $13 billion in sales last quarter — the highest-selling drug class globally. But a surgeon who still practices emergency medicine is seeing side effects the clinical trials didn't predict. Ali Pashazadeh (Treehill Partners) is a surgeon-turned-banker who still works the ER. Jon Rees (MitoRx Therapeutics) is building next-generation obesity treatments that don't rely on appetite suppression. Together they discuss: * Why GLP-1s work — and why they're essentially a starvation response * Atypical side effects: kidney stones, visual disturbances * MitoRx: targeting mitochondria instead of appetite * The personal moments that shaped their careers Plus: Why Ali left full-time medicine after watching a team argue for 6 hours over a breast cancer patient's surgery. And what Jon wants on his gravestone. SHOW NOTES Ali Pashazadeh — Founder & CEO, Treehill Partners | Practicing Surgeon | Former Goldman Sachs, UBS, Blackstone🔗 LinkedIn: https://www.linkedin.com/in/ali-pashazadeh-8490b841/ [https://www.linkedin.com/in/ali-pashazadeh-8490b841/] Jon Rees — CEO & Co-founder, MitoRx Therapeutics🔗 LinkedIn: https://www.linkedin.com/in/jondrees/ [https://www.linkedin.com/in/jondrees/] 🎬 YouTube: https://www.youtube.com/@OpenDoorSalon [https://www.youtube.com/@OpenDoorSalon]🍎 Apple: https://podcasts.apple.com/gb/podcast/open-door-salon/id1871280945 [https://podcasts.apple.com/gb/podcast/open-door-salon/id1871280945]🌐 Website: www.opendoorsalon.com [http://www.opendoorsalon.com]
19 episoder
Kommentarer
0Vær den første til at kommentere
Tilmeld dig nu og bliv en del af Open Door Salon-fællesskabet!